TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8095622

Group type: EXPERIMENTAL
Intervention: SPf66 vaccine (n = 738)
Number of subjects: 1548

Group type: COMPARATOR
Intervention: Placebo (n = 810)
Number of subjects: 1548
Study: 3527555

Group type: EXPERIMENTAL
Intervention: 2 X 500 mg acetylsalicylic acid and 3 X 75 mg dipyridamole per day (treated group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group without medication
Number of subjects: 0
Study: 29566543

Group type: EXPERIMENTAL
Intervention: Beetroot-based gel (BG) supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nitrate-depleted gel (PLA)
Number of subjects: 12
Study: 27472567

Group type: EXPERIMENTAL
Intervention: 5% NaF varnish (four applications with one‐week interval)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual home care
Number of subjects: 51
Study: 25195352

Group type: EXPERIMENTAL
Intervention: P. oleracea seeds (500 mg) taken two times a day for one month
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (lactose) capsules taken two times a day for one month
Number of subjects: 100
Study: 22388528

Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 144
Study: 20636946

Group type: EXPERIMENTAL
Intervention: Mother's perception of maternal aggression
Number of subjects: 99
Study: 18676516

Group type: EXPERIMENTAL
Intervention: Video game intervention addressing cancer treatment and care
Number of subjects: 375

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 375
Study: 15995847

Group type: EXPERIMENTAL
Intervention: Sodium fusidate (fusidin; 500 mg orally three times daily for 4 weeks, then the same dose for two consecutive weeks a month followed by 2 weeks a month without the drug for 20 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo according to the same schedule as fusidin
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sodium fusidate (fusidin)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 12795777

Group type: EXPERIMENTAL
Intervention: Test formulation of 500 mg clarithromycin tablet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of 500 mg clarithromycin tablet
Number of subjects: 24
Study: 10332969

Group type: EXPERIMENTAL
Intervention: Self-administered joint counts (JC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Joint scores (JS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trained assessor joint counts (JC)
Number of subjects: 0
Study: 9073058

Group type: EXPERIMENTAL
Intervention: Prognostic index derived from 384 randomly selected patients
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Prognostic index tested in 111 other patients
Number of subjects: 495
Study: 1854609

Group type: EXPERIMENTAL
Intervention: Screen detected cancers
Number of subjects: 840

Group type: COMPARATOR
Intervention: Nonattenders and control group cancers
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Cancers detected at prevalence and incidence screens
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Histological characteristics of cancers
Number of subjects: 840
Study: 6135442

Group type: EXPERIMENTAL
Intervention: Physical training programme (improves maximal oxygen consumption)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Physical training programme (does not change oxygen consumption)
Number of subjects: 27
Study: 30178727

Group type: EXPERIMENTAL
Intervention: In-person counseling (PE)
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Computer-generated feedback letters (CO)
Number of subjects: 961

Group type: COMPARATOR
Intervention: Assessment only (AO)
Number of subjects: 961
Study: 30097716

Group type: EXPERIMENTAL
Intervention: Galletti-Contrino manoeuvre
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Semont-Toupet manoeuvre
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (non-overweight subjects)
Number of subjects: 204
Study: 26728978

Group type: EXPERIMENTAL
Intervention: 100 g RUTF/day
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (standard hospital diet alone)
Number of subjects: 65
Study: 24718270

Group type: EXPERIMENTAL
Intervention: Triclosan-coated PDS Plus sutures (PDS Plus)
Number of subjects: 1224

Group type: COMPARATOR
Intervention: Uncoated PDS II sutures (PDS II)
Number of subjects: 1224
Study: 22111330

Group type: EXPERIMENTAL
Intervention: Candesartan and amlodipine (combination therapy)
Number of subjects: 0
Study: 19434801

Group type: EXPERIMENTAL
Intervention: Altered vegetable intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 17728218

Group type: EXPERIMENTAL
Intervention: 2-year screening interval (Gothenburg)
Number of subjects: 17503

Group type: COMPARATOR
Intervention: 4-year screening interval (Rotterdam)
Number of subjects: 17503
Study: 15277162

Group type: COMPARATOR
Intervention: Basic diet (BD) with low calcium (224 mg Ca/d)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: BD with milk (826 mg Ca/d)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: BD with calcium lactate (802 mg Ca/d)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: BD with milk mineral isolate (801 mg Ca/d)
Number of subjects: 14
Study: 11673021

Group type: EXPERIMENTAL
Intervention: Warfarin (2.5, 5 or 7.5 mg/day) plus levetiracetam 1000 mg bid
Number of subjects: 42

Group type: COMPARATOR
Intervention: Warfarin (2.5, 5 or 7.5 mg/day) plus placebo
Number of subjects: 42

Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 42
Study: 9305422

Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vodka
Number of subjects: 0
Study: 7932170

Group type: EXPERIMENTAL
Intervention: Ethacrynic acid (EA) 100 mg administered intravenously (i.v.)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ethacrynic acid (EA) 100 mg administered orally (p.o.)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ethacrynic acid (EA) administered by both routes
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ethacrynic acid (EA) administered intravenously (i.v.)
Number of subjects: 9
Study: 3501375

Group type: EXPERIMENTAL
Intervention: Continuous prophylaxis with trimethoprim-sulfamethoxazole (5-25 mg/kg/day/p.o.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent prophylaxis with trimethoprim-sulfamethoxazole (3 days/week, 5-25 mg/kg/day/p.o.)
Number of subjects: 0
Study: 31929340

Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS) for melanoma in situ (MIS) before ACA
Number of subjects: 24678

Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS) for melanoma in situ (MIS) after ACA
Number of subjects: 24678

Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS) for rare cutaneous tumors (RCT) after ACA
Number of subjects: 24678

Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS) for melanoma in situ (MIS) after AUC
Number of subjects: 24678

Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS) for rare cutaneous tumors (RCT) after AUC
Number of subjects: 24678
Study: 29643070

Group type: EXPERIMENTAL
Intervention: Caffeine therapy
Number of subjects: 870

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 870
Study: 27083914

Group type: EXPERIMENTAL
Intervention: Sojourners (high school exchange students)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Control group (German adolescents)
Number of subjects: 457
Study: 24659891

Group type: EXPERIMENTAL
Intervention: Phlebotomy (iron depletion)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Lifestyle changes alone
Number of subjects: 38
Study: 22877848

Group type: EXPERIMENTAL
Intervention: Temozolomide (200 mg/m² on days 1-5 of every 28 days for up to six cycles)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (34.0 Gy administered in 3.4 Gy fractions over 2 weeks)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Temozolomide (200 mg/m²)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Temozolomide with MGMT promoter methylation
Number of subjects: 342

Group type: COMPARATOR
Intervention: Standard radiotherapy
Number of subjects: 342
Study: 20843910

Group type: EXPERIMENTAL
Intervention: Ontario OH patients
Number of subjects: 300

Group type: COMPARATOR
Intervention: OBRI patients
Number of subjects: 300
Study: 18852623

Group type: EXPERIMENTAL
Intervention: Mindfulness training (N=8)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Waiting-list control group (N=9)
Number of subjects: 17
Study: 16091766

Group type: EXPERIMENTAL
Intervention: Daily oral 800 IU (727 mg) of alpha‐tocopherol and 500 mg of vitamin C (n = 24)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No treatment (n = 24)
Number of subjects: 48
Study: 12204662

Group type: EXPERIMENTAL
Intervention: Clinical response assessment using WHO or RECIST criteria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integration of biological response assessment
Number of subjects: 0
Study: 10519481

Group type: EXPERIMENTAL
Intervention: Betaxolol hydrochloride ophthalmic solution 0.5%
Number of subjects: 11

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 11
Study: 7735340

Group type: EXPERIMENTAL
Intervention: Fat counseling (20 g/day fat reduction)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Calorie counseling (1000 to 1200 kcal/day)
Number of subjects: 122
Study: 2404555

Group type: EXPERIMENTAL
Intervention: Radiotherapy and combination chemotherapy (cyclophosphamide, Adriamycin, methotrexate, procarbazine)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 111
Study: 7369096

Group type: EXPERIMENTAL
Intervention: Low dose heparin (500 units by intravenous infusion every 12 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fully anticoagulated group (heparin by intravenous infusion and warfarin sodium to maintain a whole blood clotting time of 30 to 90 minutes and a prothrombin index of 10% to 35%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no anticoagulants)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (patients with cardiac failure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (patients without cardiac failure)
Number of subjects: 0
Study: 31202468

Group type: EXPERIMENTAL
Intervention: Deferiprone (30 mg/kg per day divided into two equal doses)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Deferiprone
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Deferiprone (continuation in extension study)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo to Deferiprone (in extension study)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Deferiprone–deferiprone group
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo–deferiprone group
Number of subjects: 88
Study: 28124502

Group type: EXPERIMENTAL
Intervention: Weight Bias Internalization (WBI)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: High WBI (vs. low WBI)
Number of subjects: 178
Study: 25479835

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D3 (1,25(OH)2D3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (4,000 IU/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25OHD)
Number of subjects: 0
Study: 23898612

Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscope (GSVL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope (MDLS)
Number of subjects: 40
Study: 20963404

Group type: EXPERIMENTAL
Intervention: Tipranavir/ritonavir (500 mg with 200 mg ritonavir, steady state)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Valacyclovir (single dose)
Number of subjects: 29
Study: 19415409

Group type: EXPERIMENTAL
Intervention: Rye bran
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oat powder
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Mixed meal (mixture of fibres)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Fibre-rich meals (general)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control meal (no added fibre)
Number of subjects: 13
Study: 15808927

Group type: EXPERIMENTAL
Intervention: Standardized test with 250 ml fluid meal (250 kcal: 9.4 g protein, 34.4 g carbohydrates, and 8.3 g fat) at admission
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Standardized test with 250 ml fluid meal after partial weight gain (2.8 +/- 0.1 kg; BMI 16.1 +/- 0.3 kg/m2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Standardized test with 250 ml fluid meal at discharge (weight gain: 7.6 +/- 0.5 kg; BMI 17.9 +/- 0.4 kg/m2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls (n = 6; BMI 21.1 +/- 0.7 kg/m2)
Number of subjects: 20
Study: 12429544

Group type: EXPERIMENTAL
Intervention: Southampton examination schedule
Number of subjects: 97
Study: 10487487

Group type: EXPERIMENTAL
Intervention: Postmenopausal women with CAD
Number of subjects: 55

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 55
Study: 8695462

Group type: EXPERIMENTAL
Intervention: Pre-operative visits by theatre nurses
Number of subjects: 2

Group type: COMPARATOR
Intervention: No pre-operative visits
Number of subjects: 2
Study: 1960553

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin‐3 (rhIL‐3) administered by a single intravenous (IV) bolus injection followed by subcutaneous (SC) injections once daily from day 2 to 15 at doses of 60, 125, 250, and 500 micrograms/m2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin‐3 (rhIL‐3)
Number of subjects: 30
Study: 7200788

Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31829521

Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31426321

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (400 mg/day for 3 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no magnesium supplementation)
Number of subjects: 18
Study: 28480762

Group type: EXPERIMENTAL
Intervention: 300 mg tenofovir disoproxil fumarate, 300 mg lamivudine, 400/100 mg lopinavir/ritonavir
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 300 mg tenofovir disoproxil fumarate, 300 mg lamivudine, 400 mg nevirapine
Number of subjects: 15
Study: 26218728

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (20 U for GL; 24 U for CFL)
Number of subjects: 117

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 117
Study: 23673092

Group type: EXPERIMENTAL
Intervention: Computer-driven automated weaning system (CDW group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Physician-controlled local protocol (PW group)
Number of subjects: 39
Study: 21237611

Group type: EXPERIMENTAL
Intervention: Group-based Spanish language educational program facilitated by promotores (12 centers; 161 men)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Promotores-facilitated diabetes video and discussion (13 centers; 160 men)
Number of subjects: 321
Study: 19287011

Group type: EXPERIMENTAL
Intervention: Ganciclovir (6 mg/kg iv every 12 h for 6 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Valganciclovir (ongoing trial comparing 6 weeks versus 6 months)
Number of subjects: 100
Study: 17596779

Group type: EXPERIMENTAL
Intervention: 1% DEH
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 2% DEH
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 3% DEH
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 4% DEH
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: EUH with CES
Number of subjects: 17

Group type: COMPARATOR
Intervention: EUH control
Number of subjects: 17
Study: 15684260

Group type: EXPERIMENTAL
Intervention: Combination group (0.2% ropivacaine and 0.003% morphine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine group (0.003% morphine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ropivacaine group (0.2% ropivacaine)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 11790702

Group type: EXPERIMENTAL
Intervention: Fenestrated Fontan procedure
Number of subjects: 49

Group type: COMPARATOR
Intervention: Nonfenestrated Fontan procedure
Number of subjects: 49
Study: 10506675

Group type: EXPERIMENTAL
Intervention: Tramadol (200-400 mg/day)
Number of subjects: 45
Study: 8708983

Group type: EXPERIMENTAL
Intervention: Orally dissolving tablet (ODT) containing 99mTc‐labelled cholestyramine resin
Number of subjects: 6

Group type: COMPARATOR
Intervention: 1.5 mL aqueous suspension of 99mTc‐labelled cholestyramine resin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both dosage forms (ODT and aqueous suspension)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Water‐soluble marker
Number of subjects: 6
Study: 1960302

Group type: EXPERIMENTAL
Intervention: Combination therapy with recombinant tissue‐type plasminogen activator or urokinase
Number of subjects: 288

Group type: COMPARATOR
Intervention: Urgent cardiac catheterization
Number of subjects: 288

Group type: COMPARATOR
Intervention: Mean left ventricular ejection fraction
Number of subjects: 288

Group type: COMPARATOR
Intervention: Regional infarct zone wall motion
Number of subjects: 288
Study: 7139504

Group type: EXPERIMENTAL
Intervention: Inhaled powder (200 micrograms)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled powder (400 micrograms)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aerosol (200 micrograms)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31893232

Group type: EXPERIMENTAL
Intervention: HIV-positive participants
Number of subjects: 250

Group type: COMPARATOR
Intervention: HIV-negative participants
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Number of subjects: 250
Study: 29458116

Group type: EXPERIMENTAL
Intervention: Food cues (exposure to food advertising)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Non-food cues (exposure to neutral advertising)
Number of subjects: 98
Study: 26702843

Group type: EXPERIMENTAL
Intervention: 25-gauge vitrectomy with 7,500 cuts per minute (cpm) probes (7,500 Group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: 25-gauge vitrectomy with 5,000 cpm probes (Standard Group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Comparison of core vitrectomy duration between 7,500 Group and Standard Group
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study: 24787497

Group type: EXPERIMENTAL
Intervention: Weight-management (diet)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Weight-management-plus-exercise (diet-exercise)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale (GDS)
Number of subjects: 107
Study: 22726220

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 20679260

Group type: EXPERIMENTAL
Intervention: Systematic Treatment Selection (STS) for Psychodynamic Therapy (PDT)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Random Treatment Selection (RTS) for Psychodynamic Therapy (PDT)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Systematic Treatment Selection (STS) for Cognitive-Behavioural Therapy (CBT)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Random Treatment Selection (RTS) for Cognitive-Behavioural Therapy (CBT)
Number of subjects: 291
Study: 17991054

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 16368054

Group type: EXPERIMENTAL
Intervention: RSG 4 mg/day (increased to 8 mg/day) + MET 1000 mg/day (total 1500 mg/day)
Number of subjects: 766

Group type: COMPARATOR
Intervention: MET 500 mg/day (increased to 2000 mg/day)
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: RSG + MET
Number of subjects: 766
Study: 12390439

Group type: EXPERIMENTAL
Intervention: Exclusive breast-feeding for at least 4 months
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Partially or exclusively formula-fed
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Infants with AD
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Age at first introduction of solid food and diversity of solid food
Number of subjects: 1121
Study: 9801962

Group type: EXPERIMENTAL
Intervention: Panic disorder
Number of subjects: 99

Group type: COMPARATOR
Intervention: Social phobia
Number of subjects: 99

Group type: COMPARATOR
Intervention: Nonanxious controls
Number of subjects: 99
Study: 8521882

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg b.i.d for 2 weeks followed by 50 mg b.i.d for a further 2 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intravenous carvedilol followed by oral carvedilol 50 mg b.i.d for 8 weeks
Number of subjects: 23
Study: 2677532

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 945

Group type: COMPARATOR
Intervention: Aspirin, 80 mg/day
Number of subjects: 945
Study: 355043

Group type: EXPERIMENTAL
Intervention: Esophatrast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Barosperse Esophageal Paste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HD‐5000
Number of subjects: 0
Study: 29934249

Group type: EXPERIMENTAL
Intervention: 2 mA tDCS administered for 10 sessions of 20 minutes each on five consecutive days (two sessions per day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo administered for 10 sessions of 20 minutes each on five consecutive days (two sessions per day)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 2 mA tDCS
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 27221140

Group type: EXPERIMENTAL
Intervention: Volume-Controlled Ventilation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Pressure-Controlled Ventilation
Number of subjects: 41
Study: 24652107

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 0
Study: 22430640

Group type: EXPERIMENTAL
Intervention: Streaming weekly soap opera video episodes to smartphones
Number of subjects: 238

Group type: COMPARATOR
Intervention: Weekly HIV risk reduction written messages to smartphones
Number of subjects: 238